[1. Murphey MD, Walker EA, Wilson AJ, Kransdorf MJ, Temple HT, Gannon FH. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologicpathologic correlation. Radiographics. 2013; 23(5),1245–1278.10.1148/rg.235035134]Search in Google Scholar
[2. Meijer D, De Jong D, Pansuriya TC et al.Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer. 2012; 51(10), 899–909.2267445310.1002/gcc.2197422674453]Search in Google Scholar
[3. Mavrogenis AF, Gambarotti M, Angelini A et al. Chondrosarcomas revisited. Orthopedics. 2012; 35(3),e379–e390.10.3928/01477447-20120222-30]Search in Google Scholar
[4. Van Maldegem AM, Bovee JV, Gelderblom H. Comprehensive analysis of published studies involving systemic treatment for chondrosarcoma of bone between 2000 and 2013. Clin. Sarcoma Res. 2014; 4,11.10.1186/2045-3329-4-11]Search in Google Scholar
[5. Frezza AM, Cesari M, Baumhoer D et al. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. Eur. J. Cancer. 2015; 51(3),374–381.10.1016/j.ejca.2014.11.007]Search in Google Scholar
[6. Montero JC, Seoane S, Ocana A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin. Cancer Res. 2011; 17(17), 5546–5552.10.1158/1078-0432.CCR-10-26162167008421670084]Open DOISearch in Google Scholar
[7. Perez J, Decouvelaere AV, Pointecouteau T et al. Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model. PLoS ONE. 2012; 7(6),e32458.]Search in Google Scholar
[8. Rubin LL, De Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev. Drug Discov. 2006; 5(12),1026–1033.10.1038/nrd2086]Search in Google Scholar
[9. Suijker J, Oosting J, Koornneef A et al. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget. 2015; 6(14),12505–12519.10.18632/oncotarget.3723]Search in Google Scholar
[10. NCCN Guidelines Version 2.2019. Bone Cancer https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf.]Search in Google Scholar
[11. Schuetze SM, Wathen JK, Lucas DR et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 2016; 122(6),868–874.10.1002/cncr.29858]Search in Google Scholar
[12. Van Oosterwijk JG, Van Ruler MA, Briaire-De Bruijn IH et al. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. Br. J. Cancer. 2013; 109(5),1214–1222.10.1038/bjc.2013.451]Search in Google Scholar
[13. Mccubrey JA, Steelman LS, Franklin RA et al. Targeting the RAF/MEK/ERK, PI3K/ AKT and p53 pathways in hematopoietic drug resistance. Adv. Enzyme Regul. 2007; 47,64–103.10.1016/j.advenzreg.2006.12.013]Search in Google Scholar
[14. Myers AP, Cantley LC. Targeting a common collaborator in cancer development. Sci. Transl. Med. 2010; 2(48),48ps45.10.1126/scitranslmed.3001251]Search in Google Scholar
[15. Perez J, Decouvelaere AV, Pointecouteau T et al. Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model. PLoS ONE. 2012; 7(6),e32458.10.1371/journal.pone.0032458]Search in Google Scholar
[16. Zhang YX, Van Oosterwijk JG, Sicinska E et al. Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. Clin. Cancer Res. 2013; 19(14),3796–3807.10.1158/1078-0432.CCR-12-3647]Search in Google Scholar
[17. Tiet TD, Hopyan S, Nadesan P et al. Constitutive Hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. Am. J. Pathol. 2006; 168(1),321–330.10.2353/ajpath.2006.050001]Search in Google Scholar
[18. Italiano A, Le Cesne A, Bellera C et al. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/ US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann. Oncol. 2013; 24(11),2922–2926.10.1093/annonc/mdt391]Search in Google Scholar
[19. Sun Y, Guo W, Ren T et al. Gli1 inhibition suppressed cell growth and cell cycle progression and induced apoptosis as well as autophagy depending on ERK1/2 activity in human chondrosarcoma cells. Cell Death Dis. 2014; 5,e979.10.1038/cddis.2013.497]Search in Google Scholar
[20. Kostine M, Cleven AHG et al. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype, Modern Pathology advance online publication, 17 June 2016.10.1038/modpathol.2016.10827312065]Search in Google Scholar